- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
DTAB Recommends Ban on 34 Antimicrobials for Animal Use, Seeks Report on 3 Exceptions

New Delhi: The Drug Technical Advisory Board (DTAB) has recommended banning the manufacture, import, sale, distribution, and use of 34 antimicrobial medicinal products for animal use, with the exception of three categories: carboxypenicillins, cephalosporin combinations with beta-lactamase inhibitors, and phosphonic acid derivatives.
These antimicrobials are part of a list recognized by the European Union (EU) as "reserved" for the treatment of certain serious infections in humans only.
Additionally, the DTAB has requested the Department of Animal Husbandry and Dairying (DAHD) to urgently provide a report on the remaining three antimicrobials—carboxypenicillins, cephalosporin combinations with beta-lactamase inhibitors, and phosphonic acid derivatives—to support a well-informed decision-making process.
This came in line with the proposal for deliberation of matters pertaining to the prohibition of manufacturing, import, sale and distribution of 37 antimicrobial medicinal products (as laid down in the Commission Implementing Regulation (EU) 2022/1255) for growth purposes or yield increase in food-producing animals, which are reserved for the treatment of certain infections in humans.
The matter was discussed during the 92nd DTAB meeting held on April 24, 2025.
The board was apprised about the agenda. The board also noted that though these 37 antimicrobials have not been approved by CDSCO for veterinary use in the treatment of various diseases, these may be notified for prohibition in light of the request received from the Ministry of Commerce.
The representative from DAHD also explained the background on the issue. The board noted that DAHD has no objection to reserving 34 antimicrobials only for human use.
After detailed deliberation, DTAB recommended the following:
1. To prohibit the manufacture, import, sale, distribution and use of 34 antimicrobial medicinal products as laid out in EU regulation 2022/1255, except for 3 antimicrobials, viz., carboxypenicillins, combinations of cephalosporins with beta-lactamase inhibitors and phosphonic acid derivatives only, for animal use.
2. DAHD shall submit the report about these three antimicrobials at the earliest by providing the clear recommendations, which may be placed before the Chairman, DTAB for appropriate decision.
Doctor of Pharmacy
Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751